GOSERELIN ACETATE WITH OR WITHOUT FLUTAMIDE IN THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PROSTATE-CANCER
GOSERELIN ACETATE WITH OR WITHOUT FLUTAMIDE IN THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PROSTATE-CANCER
复制标题
DOI：
10.1016/s0959-8049(05)80293-x
复制
发表时间：
1993-01-01
影响因子：
8.4
通讯作者：
GALLO, G
中科院分区：
文献类型：
--
作者：
BOCCARDO, F;PACE, M;GALLO, G
从1987年3月至1990年12月，373例C期和D期前列腺癌患者被随机分为两组，一组接受单独的醋酸格列林治疗，另一组接受醋酸格列林加氟他胺治疗。中位随访时间为24个月时，两组的有效率、无进展和总存活率无显著差异。特别是，Goerelin组和联合治疗组的中位进展时间分别为18个月和24个月(P=0.09)。然而，两组D期患者的中位进展时间均为12个月。中位死亡时间分别为32个月和34个月。联合用药能更快地使前列腺酸性磷酸酶水平恢复正常，并能更迅速地缓解骨痛。然而，联合用药组中更多的患者出现了与治疗相关的副作用，如腹泻和转氨酶水平升高。同时使用醋酸格列林和氟他胺似乎不会显著改善单独使用醋酸格列林所能达到的效果。
From March 1987 to December 1990, 373 patients with stage C and D prostate cancer were randomized to receive either goserelin acetate alone or goserelin acetate plus flutamide. At a median follow-up time of 24 months, there was no significant difference in the response rate, progression-free and overall survival between the two treatment groups. In particular, median time to progression was 18 months in the goserelin arm and 24 months in the combined treatment arm (P = 0.09). However, median time to progression in stage D patients was 12 months in both treatment groups. Median time to death was 32 and 34 months, respectively. The combination regimen produced a more rapid normalisation of prostatic acid phosphatase levels and a more prompt relief of bone pain. However, significantly more patients in the combination arm experienced treatment-related side-effects such as diarrhoea and increases in transaminase levels. The concurrent use of goserelin acetate and flutamide does not seem to significantly improve the results that can be achieved with goserelin acetate alone.